3D Medicines Inc. released its Monthly Return for Equity Issuer for the period ended 30 April 2026, confirming stable capital structure and full compliance with Hong Kong Stock Exchange public-float rules.

Authorised and Issued Share Capital • Authorised share capital remained unchanged at 500.00 million ordinary shares with a par value of HKD 0.001, representing HKD 500,000 in authorised capital. • Issued shares stood at 258.18 million, identical to the balance at the close of March 2026. • The company held no treasury shares at month-end, and no new shares were issued or cancelled during the period.

Public-Float Status • As at 30 April 2026, 3D Medicines confirmed compliance with the Main Board’s 25% minimum public-float threshold.

Equity Incentive Schemes • Outstanding share options under the Share Option Scheme totalled 12.80 million, unchanged during the month. • No options were exercised; consequently, there were no funds raised from option exercises and no dilution to existing shareholders.

Other Securities • The issuer reported no outstanding warrants, convertibles, Hong Kong Depositary Receipts, or other agreements that could affect the share count.

Governance Confirmation • Director Gong Zhaolong certified that all corporate actions during the month were duly authorised and complied with applicable listing rules and legal requirements.

Overall, 3D Medicines recorded zero movements in authorised, issued or treasury shares for April 2026, maintaining a stable equity base of 258.18 million ordinary shares.